2019 · Journal of Advanced Nursing · paywalled
McLenon & Rogers
The reference systematic review and meta-analysis of needle-fear prevalence across children and adults: the quantified basis for why a proportion of any population will not present for a venous draw.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
2026
This review establishes that microsampling across blood, saliva, urine and stool matrices offers validated workflows and regulatory recognition for human biomonitoring comparable to conventional methods. It finds that these decentralised approaches enhance participant acceptability and enable screening in remote or low-resource settings.
Integrating Microsampling in Human Biomonitoring: Methodologies, Regulatory Frameworks, and Case Study Insights — Rajamani & Poongavanam, Critical reviews in analytical chemistry (paywalled) · source ↗
2025
The Egoo Phe system showed strong concordance with dried blood spot testing across 100 paired samples, with median phenylalanine 274 versus 270 μmol/L and readings a mean 4.6% higher, and high caregiver acceptance; the small sample size limits generalisability and further validation in larger cohorts is required.
Point-of-Care Testing in PKU: A New ERA of Blood Phenylalanine Monitoring — Pinto et al., Nutrients · source ↗
2025
Dried blood spot sampling matched venous serum performance for islet autoantibody detection and was considered minimally invasive and convenient by parents and stakeholders, supporting its use for decentralised screening in home or community settings.
Establishing the performance and acceptability of dried blood spot sampling to screen for islet-specific autoantibodies — Faustini et al., Diabetic medicine : a journal of the British Diabetic Association · source ↗
2025
Whole-genome sequencing of dried blood spots from 1,000 newborns identified 16 infants with high-chance results, most missed by standard screening. The 13-day turnaround and high parental acceptability show a feasible, scalable model for decentralised genomic screening.
Feasibility, acceptability and clinical outcomes of the BabyScreen+ genomic newborn screening study — Lunke et al., Nature medicine · source ↗
2024
In 91 children and adults, capillary C-peptide taken with the TAP device matched venous sampling with 100% sensitivity and specificity for a clinically relevant level, 200 pmol/L or above, with r = 0.996. 63% preferred it to a needle against 7% who preferred the needle, and same-day bruising was 5.5% versus 34.8% after a venous draw.
Transdermal blood sampling for C-peptide is a minimally invasive, reliable alternative to venous sampling in children and adults with type 1 diabetes — Besser et al., Diabetes Care · source ↗